It’s never too late to save a photoreceptor

James B. Hurley and Jennifer R. Chao

Department of Ophthalmology and Department of Biochemistry, University of Washington, Seattle, Washington, USA.

Recent gene therapy progress has raised the possibility that vision loss caused by inherited retinal degeneration can be slowed or prevented. Unfortunately, patients are not usually diagnosed until enough degeneration has occurred that the deterioration in vision is noticeable. Therefore, effective gene therapy must halt degeneration to stabilize and preserve any remaining vision. Gene therapy methods currently in human clinical trials rely on subretinal or intravitreal injections of adeno-associated virus to deliver the therapeutic gene. To date, long-term results in patients treated with subretinal injections for Leber congenital amaurosis have been mixed. Proposed limitations include variability in the gene delivery method and a possible point of no return, at which treatment would be ineffective. In this issue of the JCI, Koch et al. describe a well-controlled and precise mouse model for testing the ability of gene therapy to halt the progress of degeneration. Instead of viral-mediated therapeutic gene delivery, the authors induced expression of an integrated transgene at specific times during the course of photoreceptor degeneration. In Pde6b-deficient retina, this strategy halted degeneration, even when more than 70% of photoreceptors had already degenerated. The results of this study demonstrate that retinal degeneration can be stopped, even at late stages of disease.

Congenital blinding diseases

Hereditary blindness has been linked to at least 238 mutations that cause photoreceptor neurons in the retina to degenerate (1). For example, mutations in the gene that encodes the β subunit of PDE6 can cause a type of rod photoreceptor degeneration known as retinitis pigmentosa (RP) (2–4). PDE6 hydrolyzes cyclic GMP (cGMP) to 5’GMP in rods, is activated by light, and has a central role in phototransduction (5, 6). Defects in the enzymes that make cGMP from GTP also result in rod degeneration (7). For example, guanylyl cyclase deficiencies cause the inherited degenerative disease Leber congenital amaurosis type 1 (LCA1); however, the biochemical pathway that links abnormal cGMP metabolism is not fully understood (8).

Why and when do mutant photoreceptors die?

In some animal models of inherited retinal degeneration, the timing of individual rod death and the spatial distribution of dying rods appear to be random. In general, the rate at which rods degenerate in these models is simply proportional to the number of remaining rods, reminiscent of the spontaneous decay of radioactive isotopes. On the basis of these observations, Clark et al. (9) argued that degeneration of a photoreceptor is not caused by gradual accumulation of damage and instead proposed that degeneration is linked to a single random event that occurs in the context of a perturbed metabolic state on the threshold of insufficiency. Moreover, Clark and colleagues suggested that if those single events could be prevented (or if the threshold could be raised), then “the likelihood that a mutant neuron can be rescued by treatment is not diminished by age, although fewer cells will be available to rescue. Therefore, treatment at any stage of the illness is likely to confer benefit” (9).

This prediction was made in the year 2000, and since then, tremendous progress has been made in many aspects of gene therapy (10, 11). For example, one promising study (12) showed that injection of adeno-associated viruses (AAV) carrying a guanylyl cyclase–encoding gene halted degeneration of guanylyl cyclase-deficient rods in mice. This result suggested that AAV-mediated gene therapy could be used to treat human patients with guanylyl cyclase deficiencies. In fact, such studies are underway (13), but results have not been reported yet.

What limits success of gene therapy in human retina?

In human patients with retinal degeneration, gene therapy has so far largely focused on treatment of the inherited retinal degeneration LCA2, which is caused by an RPE65 deficiency. Clinical trials began more than seven years ago, and patient outcomes have been analyzed extensively. Retinal sensitivity in the treated regions of the retina improved significantly (14–16); however, over time, retinae exhibited continued thinning, and it is apparent that degeneration was not effectively stopped (17–19).

The most pessimistic explanation of the lack of efficacy is that continued thinning of the retina reflects an inherent feature of gene therapy that limits the ability to halt the progress of degeneration. While this interpretation seems unlikely, it is a challenge to rigorously exclude the hypothesis that damage accumulates in photoreceptors to a point of no return, where the trajectory to death is irreversible (18). Alternatively, the continued retinal thinning may instead reflect only a technical limitation, such as insufficient delivery of the virus, or damage caused by temporary detachment of the neurosensory retina, especially in the subfoveal region, that pre-

Related Article: p. 3704

Conflict of interest: The authors have declared that no conflict of interest exists.
Reference information: J Clin Invest. 2015;125(9):3424–3426. doi:10.1172/JCI83194.
can halt degeneration. Importantly, this strategy was able to show that expression of $Pde6b$ completely halts progression of photoreceptor degeneration in $Pde6b$-deficient retinae, regardless of the severity of photoreceptor cell loss. Specifically, Koch et al. devised an elegant genetic strategy that bypasses the need for AAV-mediated gene delivery (Figure 1). The authors engineered a mouse in which a therapeutic gene can be activated on demand in a manner that directly stimulates photoreceptor degeneration and evaluates the effect of rescuing the defect at that point (Figure 1A). This approach allows for the evaluation of the point of no return for gene therapy to treat retinal degeneration in a controlled manner.

New strategy evaluates the point-of-no-return hypothesis

In this issue, Koch et al. (21) describe a new, highly effective strategy to directly evaluate how well expression of a gene can halt degeneration. The authors used a mouse model in which photoreceptor degeneration is induced by a genetic mutation in the $Pde6b$ gene, which encodes for the PDE6 enzyme that degrades cyclic AMP in photoreceptors. By using a conditional gene activation system based on Cre/LoxP technology, they were able to activate the therapeutic gene expression at different stages of disease progression. The results showed that expression of the therapeutic gene at an early stage completely halted degeneration, while expression at a later stage had no effect. This strategy provides a new approach to evaluate the efficacy of gene therapy for retinal degeneration and could have implications for the further development of gene therapies for other degenerative diseases.

Figure 1. Strategy that allows evaluation of the point of no return for gene therapy to treat retinal degeneration. (A) Schematic of the genetic strategy developed by Koch et al. (21) to stimulate photoreceptor degeneration and evaluate the effect of rescuing the defect on demand by injecting the mouse with tamoxifen at different points during disease progression. The mouse has two different $Pde6b$ alleles. One allele produces a mostly inactive protein as the result of an H620Q substitution. The other allele is normal, but it is interrupted by a floxed stop cassette. The very low PDE6 activity in the retinae of these mice causes rod photoreceptors to degenerate. (B) The $Pde6g$ promoter is used to express CreERT2 in rods, and when the mouse is injected with tamoxifen, CreERT2 is activated and able to excise the stop cassette, resulting in expression of active PDE6. (C) In the absence of intervention, photoreceptors degenerate over time, resulting in vision loss. Tamoxifen-induced expression of active PDE6 at four or eight weeks of age halts degeneration. Although not shown in this schematic, the retinae continued to be stable out to 52 weeks of age.
degenerating retina. First, mice were generated with two different alleles of \textit{Pde6b}, which encodes the PDE6β subunit. One allele carried a mutation that partially inactivates the enzyme and causes rods to degenerate. The other \textit{Pde6b} allele was normal, except that it was interrupted by a floxed insertion that blocks \textit{Pde6b} expression. This floxed \textit{Pde6b} allele is designed to be inactive in the absence of Cre-driven recombination. These mice also harbor a rod-specific, tamoxifen-inducible Cre; therefore, expression of a normal PDE6β subunit within all remaining rod cells can be activated at any time by tamoxifen injection. Once Koch et al. confirmed that \textit{Pde6b} and Cre were expressed in rods as predicted, they used the engineered mice to test whether progression of degeneration could be halted by inducing normal \textit{Pde6b} expression at several different time points during the course of degeneration. Remarkably, expression of \textit{Pde6b} completely impeded the progression of degeneration, even when less than 30% of photoreceptors remained.

Together, these findings show that restoration of a key protein can halt progression of a degenerative disease. This demonstration has significant implications for the treatment of retinal degeneration in humans, because patients generally do not seek care until after substantial photoreceptor loss has caused a noticeable deterioration of vision. These results are also consistent with the idea that widespread restoration of gene expression and rod photoreceptor rescue throughout the retina prevents further cone and rod degeneration that otherwise would occur by non-cell-autonomous mechanisms.

**Etiology matters**

The ability of induced gene expression to halt degeneration is important; however, this strategy may or may not apply to all types of retinal degeneration. For example, a key difference between degeneration in RP, LCA1, and LCA2 is that the defect originates in photoreceptors in RP and LCA1, whereas it originates in the retinal pigment epithelium (RPE) in LCA2. Additionally, RP- and LCA1-associated mutations perturb guanine nucleotide metabolism, whereas LCA2-causing mutations disrupt the visual cycle and cause massive accumulation of retinyl esters in the RPE (22).

The diverse etiologies of these and other different types of degeneration could influence how well different inherited retinal diseases respond to gene therapy. The strategy that Koch et al. devised (21) is well controlled and precise and bypasses the uncertainty and variability associated with AAV injections. Gene therapists should have a tool that helps them predict how well each type of degenerative disease will respond to gene therapy and perhaps how to optimize the response. When inducible Cre becomes available in other cell types such as RPE, the genetic strategy devised by Koch et al. could provide an effective way to make those types of predictions for LCA2 and other types of retinal degeneration.

**Acknowledgments**

The authors acknowledge support from NIH grants EY06641 (to J.B. Hurley), EY017863 (to J.B. Hurley), and EY019714 (to J.R. Chao). We thank John Flannery for helpful discussions.

**Address correspondence to:** James B. Hurley, Department of Biochemistry, UW Box 357350, University of Washington, 1705 NE Pacific St., Seattle, Washington 98195, USA. Phone: 206.543.2871; E-mail: jbhhh@uw.edu.